Chugai Enhances Kidney Disease Portfolio with Renalys Acquisition
Chugai has signed a definitive stock agreement to purchase Japan-based Renalys Pharma, expanding its kidney disease portfolio.
Through this acquisition, Chugai will secure exclusive rights to develop and market Renalys' sparsentan in South Korea, Japan, and Taiwan.
- Sparsentan is a dual endothelin and angiotensin II receptor antagonist.
- Initially developed by Travere Therapeutics, it has secured approval in Europe and the US to treat IgA nephropathy (IgAN).
- Renalys is currently progressing the oral therapy in the Japanese market.
No direct quote available in the text.
Author's summary: Chugai acquires Renalys to enhance its kidney disease portfolio.
More News
- Congress gridlocked on key issues as year-end deadline looms
- Flight Booking, Cheap Flights, Air Tickets at Lowest Fare
- Breaking: Loyalist troops foil coup attempt in Benin
- Benin authorities say coup attempt foiled, President Talon safe
- Hundreds stranded after IndiGo canceled 1,000 flights in India air travel chaos
- No quick fix for ‘tiresome’ M50 gridlock, Minister says
- Heavy rain gridlocks KL traffic
- Babar Azam, Mohammad Rizwan in focus: PCB clears Big Bash NOCs for Pakistan players, but with a catch
- Cheap Domestic Flights in United States of America
- Commuters hot under the collar as snow, ice gridlock roads across Seoul